Campbell & Co Investment Adviser’s Pacira BioSciences PCRX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$500K	Buy	+19,707	New	+$466K	0.03%	771
2026 Q1	–	Sell	-78,345	Closed	-$2.03M	–	1336
2025 Q4	$2.03M	Buy	+78,345	New	+$1.86M	0.1%	331
2024 Q4	–	Sell	-18,913	Closed	-$285K	–	1288
2024 Q3	$285K	Buy	18,913 +1,639	+9%	+$28K	0.02%	924
2024 Q2	$494K	Buy	17,274 +4,569	+36%	+$130K	0.04%	660
2024 Q1	$371K	Sell	12,705 -12,726	-50%	-$391K	0.03%	827
2023 Q4	$858K	Buy	25,431 +17,432	+218%	+$510K	0.08%	456
2023 Q3	$245K	Buy	+7,999	New	+$288K	0.03%	794
2023 Q2	–	Sell	-14,087	Closed	-$575K	–	1063
2023 Q1	$575K	Sell	14,087 -7,429	-35%	-$296K	0.11%	366
2022 Q4	$831K	Buy	+21,516	New	+$1.05M	0.2%	136
2022 Q3	–	Sell	-21,511	Closed	-$1.25M	–	872
2022 Q2	$1.25M	Buy	+21,511	New	+$1.41M	0.34%	43
2022 Q1	–	Sell	-9,566	Closed	-$576K	–	853
2021 Q4	$576K	Buy	+9,566	New	+$527K	0.2%	159

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Campbell & Co Investment Adviser's PCRX Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 19,707 shares worth $500K. The stake represents 0.03% of the portfolio and ranks #771 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in PCRX as recently as Q4 2025.

Campbell & Co Investment Adviser first reported a position in PCRX in Q4 2021 and has held it in 11 quarters since. The position peaked at $2.03M in Q4 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Campbell & Co Investment Adviser held 19,707 shares of Pacira BioSciences worth $500K as of Q2 2026.
Pacira BioSciences was a new Campbell & Co Investment Adviser position in Q2 2026.
Pacira BioSciences made up 0.03% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #771 holding.
Campbell & Co Investment Adviser first reported a position in Pacira BioSciences in Q4 2021 and has held it in 11 quarters since.
Campbell & Co Investment Adviser's Pacira BioSciences position peaked at $2.03M in Q4 2025.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.